Template:BNP value
Péptido natriurético cerebral (BNP)[1]
- Medición
- <100 pg/mL: Negativa para insuficiencia cardíaca aguda (Sn 90%, VPN 89%)
- 100-500 pg/mL: Indeterminada (Considerar diagnóstico diferencial y probabilidad pre-prueba)
- >500 pg/mL: Positiva para insuficiencia cardíaca aguda (Sp 87%, VPP 90%)
- Combinación de BNP con juicio clínico 94% sensible 70% específico (comparado con 49% sn y 96% spec juicio clínico solo) [2]
NT-proBNP[3][4][5]
- <300 pg/mL → Insuficiencia cardíaca improbable
- Insuficiencia cardíaca probable en:
- >450 pg/mL en edad < 50 años
- >900 pg/mL en 50-75 años
- >1800 pg/mL en > 75 años
- ↑ Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161-167. doi:10.1056/NEJMoa020233.
- ↑ McCullough et al. B-Type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from breathing not properly (BNP) multinational study. Circulation. 2002:DOI: 10.1161/01.CIR.0000025242.79963.4
- ↑ Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006 Feb. 27(3):330-7.
- ↑ Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005 Feb 17. 352(7):666-75.
- ↑ Moe GW, Howlett J, Januzzi JL, Zowall H,. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation. 2007 Jun 19. 115(24):3103-10.